WO2007070907A3 - Therapeutic compositions - Google Patents
Therapeutic compositions Download PDFInfo
- Publication number
- WO2007070907A3 WO2007070907A3 PCT/AT2006/000530 AT2006000530W WO2007070907A3 WO 2007070907 A3 WO2007070907 A3 WO 2007070907A3 AT 2006000530 W AT2006000530 W AT 2006000530W WO 2007070907 A3 WO2007070907 A3 WO 2007070907A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- therapeutic compositions
- leukemia
- orf15δ
- hectd1δ
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Composition for the treatment of leukemia, in particular of acute lymphoblastic leukemia, comprising antigen-presenting cells loaded with a protein or an immunogenic isoform-specific fragment thereof selected from the group consisting of HECTD1Δ (SEQ ID No. 1), CX-ORF15Δ (SEQ ID No. 2), hCAP-EΔ (SEQ ID No. 3) and combinations thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATA2051/2005 | 2005-12-21 | ||
AT20512005 | 2005-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007070907A2 WO2007070907A2 (en) | 2007-06-28 |
WO2007070907A3 true WO2007070907A3 (en) | 2007-10-04 |
Family
ID=37758639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AT2006/000530 WO2007070907A2 (en) | 2005-12-21 | 2006-12-21 | Therapeutic compositions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007070907A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2828209A1 (en) * | 2001-08-01 | 2003-02-07 | Cytomics Systems | New nucleic acid encoding HECT-domain polypeptides, useful e.g. for treatment of cancer or inflammation, also new proteins, antibodies and modulators |
US20030072767A1 (en) * | 1998-09-30 | 2003-04-17 | Alexander Gaiger | Compositions and methods for WT1 specific immunotherapy |
WO2003072068A2 (en) * | 2002-02-27 | 2003-09-04 | University Of South Carolina | Targeted immunotherapy of acute lymphoblastic leukemia (all) |
-
2006
- 2006-12-21 WO PCT/AT2006/000530 patent/WO2007070907A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030072767A1 (en) * | 1998-09-30 | 2003-04-17 | Alexander Gaiger | Compositions and methods for WT1 specific immunotherapy |
FR2828209A1 (en) * | 2001-08-01 | 2003-02-07 | Cytomics Systems | New nucleic acid encoding HECT-domain polypeptides, useful e.g. for treatment of cancer or inflammation, also new proteins, antibodies and modulators |
WO2003072068A2 (en) * | 2002-02-27 | 2003-09-04 | University Of South Carolina | Targeted immunotherapy of acute lymphoblastic leukemia (all) |
Non-Patent Citations (9)
Title |
---|
CHEN YT, SCANLAN MJ, OBATA Y, OLD LJ: "Principles and practice of biologic therapy of cancer, 3rd ed." Chapter 16.7: "Identification of human tumor antigens by serological expression cloning (SEREX)", 2000, LIPPINCOTT, WILLIAMS, AND WILKINS, PHILADELPHIA PA, XP001536304 * |
DATABASE EMBL [online] 7 March 2006 (2006-03-07), DOHNAL,A.M., PANZER-GRUEMAYER,R.E.: "Anti-leukemia-specific humoral immune response in children with T- lineage acute lymphoblastic leukemia.", XP002431589, retrieved from EBI accession no. Q2KQ74 * |
DATABASE SEREX [online] Ludwig Institute for Cancer Research; 9 June 2003 (2003-06-09), XP002431588, retrieved from HTTP://WWW2.LICR.ORG/CANCERIMMUNOMEDB/SHOWGENE.PHP?GENE=ACTR5 * |
HOUTENBOS ILSE ET AL: "Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation.", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 52, no. 7, July 2003 (2003-07-01), pages 455 - 462, XP009083043, ISSN: 0340-7004 * |
KOKHAEI P ET AL: "Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL.", LEUKEMIA (BASINGSTOKE), vol. 17, no. 5, May 2003 (2003-05-01), pages 894 - 899, XP009083041, ISSN: 0887-6924 * |
LING MIN ET AL: "Prevalence of antibodies against proteins derived from leukemia cells in patients with chronic myeloid leukemia", BLOOD, vol. 92, no. 12, 15 December 1998 (1998-12-15), pages 4764 - 4770, XP009083024, ISSN: 0006-4971 * |
MAYORDOMO JOSE I ET AL: "Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines", STEM CELLS (MIAMISBURG), vol. 15, no. 2, 1997, pages 94 - 103, XP009083060, ISSN: 1066-5099 * |
OELKE M ET AL: "Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 6, no. 5, May 2000 (2000-05-01), pages 1997 - 2005, XP002352660, ISSN: 1078-0432 * |
PREUSS KLAUS-DIETER ET AL: "Analysis of the B-cell repertoire against antigens expressed by human neoplasms.", IMMUNOLOGICAL REVIEWS, vol. 188, October 2002 (2002-10-01), pages 43 - 50, XP002431513, ISSN: 0105-2896 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007070907A2 (en) | 2007-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004034990A3 (en) | Methods and compositions for use in treating cancer | |
WO2006074051A3 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION | |
AU2003273276A1 (en) | Methods and compositions for the preservation of cells, tissues or organs in the vitreous state | |
WO2005011592A3 (en) | Substituted indazole-o-glucosides | |
AU2002342091A1 (en) | Silicone priming compositions, articles and methods_____________ | |
WO2005012243A3 (en) | Substituted indole-o-glucosides | |
WO2007067682A3 (en) | In vivo cell surface engineering | |
WO2002080754A3 (en) | Methods for using annexin for detecting cell death in vivo and treating associated conditions | |
WO2005030797A3 (en) | Melanocortin receptor agonists | |
WO2003011115A3 (en) | Peptide-based multimeric targeted contrast agents | |
WO2002024234A3 (en) | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye | |
IL190796A0 (en) | Compositions and their uses for gene therapy of bone conditions | |
WO2006042230A8 (en) | Medical devices and methods of making the same | |
WO2006010070A3 (en) | Compositions and methods related to peptides that selectively bind leukemia cells | |
WO2007053512A3 (en) | Novel protein transduction domains and uses therefor | |
WO2004058153A9 (en) | Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. | |
WO2009025116A1 (en) | Cdh3 peptide and medicinal agent comprising the same | |
MXPA02012249A (en) | Peptides, compositions and methods for the treatment of burkholderia cepacia. | |
WO2005094761A8 (en) | Hair treatment compositions comprising a disaccharide, a di-acid and a source of ammonium ions | |
WO2003048205A3 (en) | Novel proteins with il-6 inhibiting activity | |
WO2004098536A3 (en) | Anti-viral activity of cathelicidin peptides | |
WO2007067795A3 (en) | Methods for identifying and targeting tumor stem cells based on nuclear morphology | |
AU2003233222A1 (en) | Aqueous polyurethane preparations | |
WO2004080477A8 (en) | Aplidine for multiple myeloma treatment | |
WO2004078927A3 (en) | Progenitor cells and methods of using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06827960 Country of ref document: EP Kind code of ref document: A2 |